Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
A Phase 1b Dose Escalation and Expansion Study of CAN04, a Monoclonal Antibody Targeting IL1RAP, in Combination With Modified FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04935359 -
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
|
Phase 3 | |
| Active, not recruiting |
NCT05095064 -
Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
|
||
| Active, not recruiting |
NCT05039177 -
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04888312 -
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT04390763 -
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
|
Phase 2 | |
| Not yet recruiting |
NCT06206876 -
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Completed |
NCT02501902 -
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
|
Phase 1 | |
| Active, not recruiting |
NCT04581343 -
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients
|
Phase 1 | |
| Completed |
NCT02558894 -
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
|
Phase 2 | |
| Terminated |
NCT02732938 -
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
|
Phase 2 | |
| Recruiting |
NCT05472259 -
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
|
Phase 2 | |
| Recruiting |
NCT06445062 -
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02600949 -
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05630183 -
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT02583477 -
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT04329949 -
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
| Terminated |
NCT02101021 -
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
| Suspended |
NCT05685602 -
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06398587 -
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 2 |